Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
163.00
-19.60 (-10.73%)
Oct 8, 2025, 4:00 PM EDT - Market closed
Spruce Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts that cover Spruce Biosciences stock have a consensus rating of "Hold" and an average price target of $131.25, which forecasts a -19.48% decrease in the stock price over the next year. The lowest target is $37.5 and the highest is $225.
Price Target: $131.25 (-19.48%)
Analyst Consensus: Hold
* Price targets were last updated on Apr 16, 2025.
Analyst Ratings
The average analyst rating for Spruce Biosciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $113 → $38 | Hold | Maintains | $113 → $38 | -76.99% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 16, 2024 |
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 12, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades $225 | Buy → Hold | Downgrades | $225 | +38.04% | Dec 11, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $150 → $113 | Hold | Reiterates | $150 → $113 | -30.98% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
1.02M
from 4.91M
Decreased by -79.23%
Revenue Next Year
n/a
from 1.02M
EPS This Year
-65.03
from -96.39
EPS Next Year
-11.54
from -65.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.1M | n/a | |
| Avg | 1.0M | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -57.2% | - | |
| Avg | -79.2% | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -53.55 | -11.88 | |
| Avg | -65.03 | -11.54 | |
| Low | -74.97 | -11.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.